Phase 1a/1b dose-escalating trial of VE303 in healthy volunteers.

Trial Profile

Phase 1a/1b dose-escalating trial of VE303 in healthy volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs VE 303 (Primary)
  • Indications Clostridium-difficile-infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 07 Dec 2017 According to a Vedanta Biosciences media release, this study is expected to be completed in the first half of 2018.
    • 07 Dec 2017 Status changed from planning to recruiting, according to a Vedanta Biosciences media release.
    • 07 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top